Silence Therapeutics plc (SLN)

Every figure this model derived for SLN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 3,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 72,054,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 94,281,000 AssetsCurrent 2026-06-30
current liabilities 12,714,000 LiabilitiesCurrent 2026-06-30
equity 38,471,000 StockholdersEquity 2026-06-30
ocf -42,263,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 615,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 6,204,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SLN on one particular measure came for.

RatioValue
current ratio7.42
current ratio reported7.42
deferred revenue growth-100.0
dilution pct2.12
revenue growth-97.74
revenue growth per share-97.78
rule of 40-11204.57
sbc pct revenue1008.78

What to be careful about

What this model itself distrusts about SLN's figures. Written by the derivation as it ran, not added afterwards.